AbbVie (NYSE:ABBV) Shares Up 3.4% – Time to Buy?

Shares of AbbVie Inc. (NYSE:ABBV) traded up 3.4% during mid-day trading on Friday . The stock traded as high as $253.35 and last traded at $251.52. 52,480,576 shares traded hands during trading, an increase of 636% from the average daily volume of 7,134,102 shares. The stock had previously closed at $243.14.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analysts Set New Price Targets

Several brokerages recently weighed in on ABBV. Canaccord Genuity Group boosted their price objective on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $253.81.

AbbVie Trading Up 3.4%

The stock’s 50-day moving average price is $215.16 and its 200-day moving average price is $219.18. The stock has a market cap of $444.38 billion, a price-to-earnings ratio of 123.90, a P/E/G ratio of 0.77 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the company posted $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Institutional Investors Weigh In On AbbVie

Large investors have recently added to or reduced their stakes in the business. Hamilton Wealth LLC increased its holdings in AbbVie by 0.4% in the first quarter. Hamilton Wealth LLC now owns 22,320 shares of the company’s stock worth $4,854,000 after purchasing an additional 96 shares in the last quarter. LFG Wealth Partners LLC increased its holdings in shares of AbbVie by 11.4% during the first quarter. LFG Wealth Partners LLC now owns 6,903 shares of the company’s stock valued at $1,501,000 after acquiring an additional 705 shares in the last quarter. FAS Wealth Partners Inc. increased its holdings in shares of AbbVie by 3.6% during the first quarter. FAS Wealth Partners Inc. now owns 30,629 shares of the company’s stock valued at $6,661,000 after acquiring an additional 1,064 shares in the last quarter. Pine Valley Investments Ltd Liability Co raised its position in shares of AbbVie by 2.3% during the first quarter. Pine Valley Investments Ltd Liability Co now owns 75,560 shares of the company’s stock worth $16,434,000 after purchasing an additional 1,727 shares during the period. Finally, Evansbrook LLC raised its position in shares of AbbVie by 1.4% during the first quarter. Evansbrook LLC now owns 3,531 shares of the company’s stock worth $768,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.